Cargando…
Tivozanib: a novel VGFR inhibitor for kidney cancer
Treatment of kidney cancer has changed over the past 10 years with the approval of several targeted agents. These drugs are given on a long term base and toxicity is an issue for most patients. Despite improvement compared to immunotherapy, most patients will progress on these drugs. There is a need...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708224/ https://www.ncbi.nlm.nih.gov/pubmed/26816733 http://dx.doi.org/10.3978/j.issn.2223-4683.2012.07.04 |